Akershus University Hospital

Running trials

• Not yet recruiting

  METIMMOX-3 for patients with recently diagnosed bowel cancer with spread to other organs

  2026-526317-29-00· Phase 2· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Source

• Not yet recruiting

  Vi-Siblin for LARS: A randomized, controlled trial.

  2024-514541-11-00· Phase 2· Source

• Not yet recruiting

  A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.

  2025-521269-28-00· Phase 2· Source

• Recruiting

  Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)

  2023-509022-22-00· Phase 3· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· Source

• Recruiting

  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  2024-513122-27-00· Phase 3· Source

• Recruiting

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· Phase 3· Source

• Recruiting

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  NCT06488482· Phase 3· Source

• Recruiting

  Atorvastatin in chronic migraine (StainMigChronic)

  2022-502177-42-02· Phase 2· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Source

• Recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05923073· Phase 3· Source

• Recruiting

  IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial)

  2023-506620-87-00· Phase 4· Source

• Recruiting

  Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

  2022-500587-35-01· Phase 3· Source

• Recruiting

  SACK

  2022-501600-10-00· Phase 3· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Source

• Active, not recruiting

  Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with extensive stage small-cell lung cancer?

  NCT05223647· Phase 3· Source

• Active, not recruiting

  Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis

  NCT04749667· Phase 1/2· Source

• Recruiting

  Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

  NCT04588285· Phase 2· Source

• Active, not recruiting

  Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

  NCT04578639· Phase 3· Source

• Recruiting

  The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

  NCT04513639· Phase 2/3· Source

• Recruiting

  Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

  NCT03968393· Phase 4· Source

• Recruiting

  ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

  NCT03903835· Phase 3· Source

• Completed

  Prevention of Cardiac Dysfunction During Breast Cancer Therapy

  NCT03760588· Phase 2· Source

• Active, not recruiting

  Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

  NCT03540420· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease3 recruiting
• Stroke3 recruiting
• Atrial fibrillation2 recruiting
• Colorectal cancer2 recruiting
• Lung cancer2 recruiting
• Multiple sclerosis2 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Gastric and oesophageal cancer1 recruiting
• High blood pressure1 recruiting
• Lewy body dementia1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  The TAF-MS study

  2023-503814-62-00· Phase 2· Source

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· Source